A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Description: 

To evaluate the effect of the addition of idelalisib tobendamustine/rituximab on progression-free survival (PFS) in subjects with previously treated indolent non-Hodgkin lymphoma (iNHL).

Study Number: 

PH 240713

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01732926

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.